<DOC>
	<DOCNO>NCT03091855</DOCNO>
	<brief_summary>Patients screen Intermountain Medical Center Intermountain affiliate anticoagulation clinic Salt Lake City region . Patients atrial fibrillation undergo standard care , clinically approve , leave atrial appendage closure consider study . All patient follow 24 month , assess 3- , 6- , 12- , 18- 24-months post-left atrial appendage closure well visit deem necessary clinical care . All subject undergo protocol-specified laboratory test complete 6 standard , validated questionnaire follow-up visit , except 3-month visit one questionnaire administer .</brief_summary>
	<brief_title>PLUG Dementia Trial</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>1 . Male female &gt; 65 year age 2 . Atrial fibrillation document electrocardiogram , ambulatory event monitor , telemetry within 6 month enrollment 3 . Moderate risk thromboembolism base upon CHADS2 score CHADS2 Vasc score â‰¥2 . 4 . Recipient leave atrial appendage closure system within 3 month study enrollment 5 . Ability complete minimental status evaluation 6 . Ability independently comprehend complete quality life dementia questionnaire . 7 . Ability provide inform consent study participation 8 . Willing able comply prescribe followup test schedule evaluation . 1 . History form dementia 2 . A life expectancy le 24 month 3 . Inability comply followup schedule 4 . An upper age limit use participation inclusion criterion meet . 5 . Participation clinical trial involve investigational market drug within 30 day prior entry study ; 6 . Other condition opinion Principal Investigator may increase risk subject and/or compromise quality clinical trial ; 7 . The Principal Investigator ( ) determine ( ) subject eligible participation research study .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>